HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice.

Abstract
A systemically active, nonpeptidic delta receptor-selective agonist, (+-)-4-((alpha-R*)-alpha-((2S*,5R*)-4-allyl-2,5-dimethyl-1-piperazinyl) -3- hydroxybenzyl)-N,N-diethylbenzamide (BW373U86), produced a brief, nonlethal convulsion in mice. The behavioral pattern of convulsion produced by pentylenetetrazol was similar to that produced by systemic administration of BW373U86. Although several episodes of convulsion occurred with pentylenetetrazol, BWB373U86 produced a single, brief episode. Naltrexone (10.0 and 100 mg/kg) and naltrindole (1.0, 3.2 and 10.0 mg/kg), but not midazolam (0.32 mg/kg), produced dose-dependent rightward shifts in the potency of BW373U86 to induce a convulsion. A dose of 3.2 mg/kg of midazolam completely eliminated convulsions induced by BW373U86. Midazolam (0.32 and 3.2 mg/kg), but not naltrindole (3.2 and 32.0 mg/kg), produced parallel rightward shifts in the pentylenetrazol dose-effect curve. Pretreatment with a single injection of BW373U86 (3.2, 10.0, 32.0 or 100 mg/kg) produced a dose-related reduction in the capacity of BW373U86 to induce a second convulsion. Recovery of sensitivity to BW373U86 did not return to control levels for up to 2 weeks after pretreatment with a single injection of 32.0 mg/kg of BW373U86. Naltrindole (3.2 mg/kg) administered within 1 hr, but not at 2 hr, after a pretreatment dose of 10.0 mg/kg of BW373U86 prevented the refractoriness (tolerance) induced by the single dose of BW373U86. These data suggest that the convulsions as well as the tolerance induced by BW373U86 were initiated through delta opioid receptors.
AuthorsS D Comer, E M Hoenicke, A I Sable, R W McNutt, K J Chang, B R De Costa, H I Mosberg, J H Woods
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 267 Issue 2 Pg. 888-95 (Nov 1993) ISSN: 0022-3565 [Print] United States
PMID8246164 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Anticonvulsants
  • Benzamides
  • Enkephalins
  • Piperazines
  • Receptors, Opioid, delta
  • Receptors, Opioid, mu
  • BW 373U86
  • Enkephalin, Leucine
  • Naltrexone
  • enkephalin, Ser(2), Leu(5), Thr(6)-
  • Enkephalin, D-Penicillamine (2,5)-
  • Midazolam
  • Pentylenetetrazole
Topics
  • Amino Acid Sequence
  • Animals
  • Anticonvulsants (pharmacology)
  • Benzamides (antagonists & inhibitors, toxicity)
  • Dose-Response Relationship, Drug
  • Drug Tolerance
  • Enkephalin, D-Penicillamine (2,5)-
  • Enkephalin, Leucine (analogs & derivatives, toxicity)
  • Enkephalins (toxicity)
  • Kindling, Neurologic
  • Male
  • Mice
  • Mice, Inbred Strains
  • Midazolam (pharmacology)
  • Molecular Sequence Data
  • Naltrexone (pharmacology)
  • Pentylenetetrazole (pharmacology)
  • Piperazines (antagonists & inhibitors, toxicity)
  • Receptors, Opioid, delta (antagonists & inhibitors, drug effects, physiology)
  • Receptors, Opioid, mu (antagonists & inhibitors)
  • Seizures (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: